DSCSA data exchange has matured into daily operations, but the coming NDC-12 shift and a national licensure standard add new work streams before old ones are fully settled.
|Articles|April 11, 2022
AmerisourceBergen Launches $150M Venture Capital Fund
New venture capital fund AB Health Ventures will partner with innovative startup companies in transforming healthcare
Advertisement
AmerisourceBergen (Conshohocken, PA) has announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will invest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals globally.
AB Health Ventures will initially launch with $150 million allocated for investment in early-to mid-stage health-related startups around the world. The fund will prioritize investments in entrepreneurs who are pursuing bold ideas in areas such as the future of pharmacy and distribution, clinical development and commercialization of pharmaceuticals, practice solutions for healthcare providers, and animal health.
AB Health Ventures is a wholly-owned subsidiary of AmerisourceBergen that “will utilize the company‘s deep expertise, global footprint, and strong relationships with stakeholders across the pharmaceutical supply chain to add value to entrepreneurs looking for partners to help grow their businesses,” the company reports. AmerisourceBergen will support startups in helping them rapidly prototype solutions, test with pilots, and accelerate scale through commercialization.
For more information, visit
Advertisement
Related to this article
Liberty Dewey of Cardinal Health breaks down the NDC-12 transition timeline, the four work streams driving it and why the biggest risk sits in trading partner handoffs.
Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this Pharma Pulse special.
An FTC settlement moved one PBM aggregator onshore, but manufacturers still lack contract-level clarity on what affiliated fees actually buy.
Simvera PSP applies queueing science so manufacturers can test the cost and patient impact of hub staffing decisions before locking them in.
Gregg Gorniak explains how AI, RFID and serialized data are helping trading partners move DSCSA compliance from a regulatory checkbox to a source of shared operational value.
As HRSA's 340B Rebate Model Pilot moves toward its effective date, Valerie Bandy, PharmD, of Tecsys explains what drug-by-drug rebate tracking really demands from hospital and health system pharmacies.
Pharma pricing shifts beyond PBM rebates as Medicare and cash channels reshape launches, WAC cuts and access strategies.
Advertisement
Advertisement